Business
ZIIHERA Plus TEVIMBRA and Chemotherapy: A Potential New Standard for First-Line HER2+ Advanced GEA
SAN CARLOS, Calif., January 06, 2026--BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced full results from the Phase 3 HERIZON-GEA-01 trial evaluating ZIIHERA® (zanidatamab), a HER2-targeted bispecific antibody, in combination with chemotherapy, with and without PD-1 inhibitor TEVIMBRA® (tislelizumab), as a first-line treatment for HER2-positive (HER2+) locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). These data, includin
About this update from Beone Medicines Ltd. Class A
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":28492,"height":5743,"url":"https://media.zenfs.com/en/business-wire.com/b1ea9ab0547c176ae98096c02cf1fbf2"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/Cnm_m04Z60X6Ld24A.ptHw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTE5NDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/b1ea9ab0547c176ae98096c02cf1fbf2","width":960,"height":194},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/ThmfZAPdDxmdygdqd43rFQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD00ODQ7Y2Y9d2VicA--/https://media.zenfs.com/en/business-wire.com/b1ea9ab0547c176ae98096c02cf1fbf2","width":1200,"height":242}},"lazy":false},{"type":"text","content":"Combination therapy showed compelling survival and disease control compared to current standard, regardless of PD-L1 status","length":123,"tagName":"p","attribs":{}},{"type":"text","content":"High GEA burden in Asia, where BeOne holds ZIIHERA rights, signals potential broad patient impact","length":97,"tagName":"p","attribs":{}},{"type":"text","content":"Results to be presented as a Late-Breaking Abstract Oral Presentation at ASCO GI on January 8, 2026","length":99,"tagName":"p","attribs":{}},{"type":"text","content":"SAN CARLOS, Calif., January 06, 2026--(BUSINESS WIRE)--BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced full results from the Phase 3 HERIZON-GEA-01 trial evaluating ZIIHERA® (zanidatamab), a HER2-targeted bispecific antibody, in combination with chemotherapy, with and without PD-1 inhibitor TEVIMBRA® (tislelizumab), as a first-line treatment for HER2-positive (HER2+) locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). These data, including the first interim overall survival (OS) analysis, will be presented as a Late-Breaking Abstract Oral Presentation (#LBA285) at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO GI) on January 8, 2026, from 8:57- 9:07 a.m. PST.","length":778,"tagName":"p"},{"type":"text","content":"HERIZON-GEA-01 met the dual primary endpoint of progression-free survival (PFS), demonstrating statistically significant and clinically meaningful improvements in both experimental arms compared to the control arm. The addition of TEVIMBRA to ZIIHERA and chemotherap...